A18.10 Tuberculosis of genitourinary system, unspecified

Name of the Condition

• Tuberculosis of genitourinary system, unspecified
• ICD Code: A18.10

Summary

Tuberculosis of the genitourinary system, unspecified, is a form of extrapulmonary tuberculosis where Mycobacterium tuberculosis infects organs of the urinary or reproductive systems without specifying the exact site. This condition typically arises from the spread of TB bacteria from a primary site, such as the lungs, and can affect structures like the kidneys, bladder, ureters, or reproductive organs. It may present with localized symptoms or systemic signs of TB.

Causes

Tuberculosis of the genitourinary system, unspecified, is caused by infection with Mycobacterium tuberculosis. The bacteria usually spread to the genitourinary tract through the bloodstream or lymphatic system from an existing TB infection elsewhere in the body, such as the lungs or lymph nodes.

Risk Factors

• Close contact with individuals who have active tuberculosis.
• Immunocompromised states, including HIV/AIDS.
• History of tuberculosis infection.
• Poor socioeconomic conditions, which increase exposure risk.
• Living in or traveling to regions with high TB prevalence.

Symptoms

• Dysuria (painful urination).
• Hematuria (blood in urine).
• Urinary frequency or urgency.
• Pelvic pain or discomfort.
• Systemic symptoms of TB, such as fever, night sweats, or weight loss.
• In reproductive organs, symptoms may include abnormal discharge, menstrual irregularities, or post-coital bleeding.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., ultrasound, CT, or MRI), and laboratory tests. Urine cultures for Mycobacterium tuberculosis may be performed, along with biopsies of affected tissues if necessary. A thorough medical history and physical examination are essential to assess for systemic TB involvement.

Treatment Options

Standard anti-tuberculosis therapy (ATT) is used, typically including a combination of drugs like isoniazid, rifampicin, ethambutol, and pyrazinamide. Treatment duration is usually 6–9 months, with close monitoring for response and side effects. Surgical intervention may be required in cases of severe organ damage or complications.

Prognosis and Follow-Up

With appropriate treatment, the prognosis is generally favorable, though recovery may take time. Regular follow-up is necessary to monitor for treatment response, potential relapse, or drug resistance. Long-term surveillance is recommended to ensure complete resolution and to address any residual symptoms.

Complications

• Kidney damage or failure.
• Urinary tract obstruction.
• Infertility or reproductive organ dysfunction.
• Spread of infection to other parts of the body.
• Drug-resistant TB, which may complicate treatment.

Lifestyle & Prevention

• Avoid close contact with individuals who have active TB.
• Maintain good hygiene and ventilation in living spaces.
• Ensure proper nutrition and overall health to support immune function.
• Follow public health guidelines for TB screening and prevention, especially in high-risk areas.

When to Seek Professional Help

Seek medical attention if you experience persistent urinary symptoms, pelvic pain, unexplained weight loss, fever, or night sweats. Early evaluation is critical for timely diagnosis and treatment to prevent complications.

Tips for Medical Coders

When coding A18.10, ensure the documentation supports an unspecified site of genitourinary TB without further specification. Verify that the diagnosis aligns with clinical findings and that no more specific site (e.g., kidney, prostate) is documented, as this would require a different code. Document the basis for the unspecified designation clearly in the medical record.